Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells

Known as: Anti-CD3 x CD20Bi-Armed ATC 
Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions… Expand
  • table 1
  • table 2
2015
2015
Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2014
2014
Targeting HER2 overexpressed breast cancer cells with anti‑HER2 monoclonal antibodies inhibits tumor growth. Here we investigated… Expand
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Anti-CD3 x anti-HER2Bi bispecific antibody… Expand
2014
2014
3075 Background: Anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) retargeting transforms activated T cells (ATC) into non… Expand
2014
2014
A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
3073 Background: : Despite improvements in the treatment of metastatic breast cancer (MBC), there are no curative treatment… Expand
2012
2012
BackgroundMyeloid-derived suppressor cells (MDSCs) are one of the major components of the immune-suppressive network, play key… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti… Expand